Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase II study.
J. Blay
Consultant or Advisory Role - GlaxoSmithKline; ImClone Systems; Novartis; Pfizer; PharmaMar; Roche
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
S. P. Chawla
Consultant or Advisory Role - Amgen; ARIAD; Epeius Biotechnologies; Merck; ZIOPHARM Oncology
Research Funding - Amgen
J. Martin Broto
No relevant relationships to disclose
E. Choy
Consultant or Advisory Role - Amgen
Honoraria - Amgen
M. Dominkus
No relevant relationships to disclose
J. Engellau
No relevant relationships to disclose
R. Grimer
Consultant or Advisory Role - Amgen (U)
Honoraria - Amgen
Research Funding - Amgen
R. M. Henshaw
Consultant or Advisory Role - Amgen (U)
Honoraria - Amgen
Research Funding - Amgen
E. Palmerini
No relevant relationships to disclose
P. Reichardt
No relevant relationships to disclose
P. Rutkowski
No relevant relationships to disclose
K. M. Skubitz
Consultant or Advisory Role - ARIAD; Johnson & Johnson; Keryx; Novartis; S M I
Research Funding - ARIAD; Bayer; Celgene; Cell Therapeutics; Daiichi Sankyo; GlaxoSmithKline; Johnson & Johnson; S M I; Schering-Plough
D. M. Thomas
Honoraria - Amgen
Y. Zhao
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Y. Qian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
I. A. Jacobs
Employment or Leadership Position - Amgen
Stock Ownership - Amgen